HST Global

HST Global FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of HST Global (HSTC) as of Oct 30, 2026 is 126.95 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 14.32 % — a change of 786.59% (higher).

FCF Conversion

126.95 %

YoY

786.59%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of HST Global is 2025 126.95 % . FCF Conversion Rate (FCF/EBITDA) of HST Global was 2024 14.32 % . It decreases by 786.59% higher compared to the previous year.

The HST Global FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
18.11 USD
Jan 1, 2018
11.83 USD
Jan 1, 2019
-21.55 USD
Jan 1, 2020
12.84 USD
Jan 1, 2021
19.76 USD
Jan 1, 2022
14.50 USD
Jan 1, 2023
14.32 USD
Jan 1, 2025
126.95 USD
The HST Global FCF Conversion history
YEARFCF ConversionYoY
126.95 %+786.59%
14.32 %-1.24%
14.50 %-26.62%
19.76 %+53.85%
12.84 %-159.61%
-21.55 %-282.17%
11.83 %-34.68%
18.11 %+42.85%
12.67 %+41.25%
8.97 %-32.49%
13.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HST Global Stock analysis

What does HST Global do? HST Global Inc is a company that focuses on the development and marketing of technology solutions for the healthcare sector. The company was founded in 2004 and is headquartered in Hampton, Virginia, USA. HST Global Inc has become a significant player in the global medical technology market in recent years and offers a wide range of products and services for medical facilities and healthcare professionals. The history of HST Global Inc is closely linked to the history of advancements in medical technology. The company has always focused on researching and developing innovative technologies that enable better and faster diagnosis, treatment, and prevention of diseases. The company has an impressive list of patents and intellectual property rights that allow it to develop innovative solutions in collaboration with its customers. HST Global Inc offers a wide range of products and services that are divided into four main areas: biotechnology, medical devices, information and communication technology, and healthcare services. The biotechnology division includes a variety of technology solutions that enable the company and its customers to develop new drugs and therapies. The medical devices division encompasses a wide range of devices and instruments used in hospitals and clinics to enable precise diagnosis and treatment of diseases. The information and communication technology division focuses on the development of software and technology solutions that enable effective and secure transmission of medical data and information. The healthcare services division offers a wide range of services tailored to the specific needs of patient groups. HST Global Inc's products and services also include a variety of solutions focused on the diagnosis and treatment of cancer and other life-threatening diseases. These products and services include technologies for cancer cell detection, development of personalized cancer treatments, and monitoring the effectiveness of cancer treatments. HST Global Inc has also specialized in developing solutions to improve the health of people in developing countries. The company has developed programs aimed at improving access to medical care and healthcare services in rural areas and developing countries. HST Global Inc relies on a combination of innovative technology and local knowledge to create solutions tailored to the needs of the local population. The business model of HST Global Inc is based on close collaboration with medical facilities and professionals. By developing innovative solutions in collaboration with its customers, the company can provide added value to its customers and meet their needs. The company also has a dedicated research and development unit that continuously develops new products and technologies to meet the ever-changing demands of the market. Overall, HST Global Inc has experienced an impressive success story in the medical technology market in recent years. The company has a strong presence in the global market and offers a wide range of products and services tailored to the needs of medical facilities and professionals. The company is also committed to expanding its expertise in biotechnology and medical technology to offer an even broader range of solutions to its customers. HST Global is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HST Global stock

FCF Conversion Rate (FCF/EBITDA) of HST Global is 126.95 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of HST Global changed from 14.32 % to 126.95 %, representing a 786.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) HST Global since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s HST Global with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — HST Global

All Key Metrics — HST Global